| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2019-04-02 |
Sangamo Therapeutics (USA - CA) Brammer Bio (USA - CA) |
large-scale AAV manufacturing |
|
manufacturing - production |
|
Production agreement |
| 2019-03-12 |
Sangamo Therapeutics (USA - CA) |
senior vice president cell therapy |
|
nomination |
|
Nomination |
| 2019-02-27 |
Sangamo Therapeutics (USA - CA) Biogen (USA - MA) |
ST-501, ST-502, and a neuromuscular target |
tauopathies including Alzheimer’s disease, synucleinopathies including Parkinson’s disease |
licensing - development - commercialisation |
Neurological diseases - Neurodegenerative diseases - Neuromuscular diseases |
Licensing agreement |
| 2019-02-22 |
Voyager Therapeutics (USA-MA) Abbvie (USA - IL) |
vectorized antibodies directed at pathological species of alpha-synuclein |
Parkinson's disease and diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein |
development - commercialisation |
Neurological diseases - Neurodegenerative diseases |
Development agreement |
| 2019-01-22 |
Voyager Therapeutics (USA-MA) |
general counsel |
|
nomination |
Neurological diseases - Neurodegenerative diseases |
Nomination |
| 2019-01-22 |
Voyager Therapeutics (USA-MA) Neurocrine Biosciences (USA - CA) |
VY-AADC, VY-FXN01 |
Parkinson’s Disease - Friedreich’s Ataxia |
development, commercialization |
Rare diseases - Neurological diseases - Neurodegenerative diseases |
Development agreement |
| 2019-01-15 |
Voyager Therapeutics (USA-MA) |
chief medical officer |
|
nomination |
Neurological diseases - Neurodegenerative diseases |
Nomination |
| 2019-00-22 |
Sangamo Therapeutics (USA - CA) |
vice president Research & Development (R&D) |
|
nomination |
|
Nomination |
| 2018-12-17 |
Voyager Therapeutics (USA-MA) The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (USA) |
Parkinson’s Disease Education Consortium, Parkinson’s Progression Markers Initiative |
Parkinson's disease |
collaboration |
Neurological diseases - Neurodegenerative diseases |
Collaboration agreement |
| 2018-11-29 |
Voyager Therapeutics (USA-MA) Brammer Bio (USA - CA) Fujifilm Diosynth Biotechnologies (USA - NC) |
AAV-based gene therapies |
|
production - manufacturing |
|
Production agreement |
| 2018-11-10 |
Abbvie (USA - IL) Sandoz (Switzerland) |
- intellectual property relating to Humira®
|
plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa, non-infectious uveitis |
licensing
- biosimilar/monoclonal antibody/TNF alpha inhibitor. Adalimumab is a monoclonal antibody that binds specifically to TNF alpha and blocks its interaction with cell surface TNF receptors. It is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
|
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Dermatological diseases |
Licensing agreement |
| 2018-10-18 |
Abbvie (USA - IL) Fresenius Kabi (Germany) |
MSB11022 - biosimilar version of Humira® (adalimumab) |
|
licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases |
Licensing agreement |
| 2018-10-18 |
Iovance Biotherapeutics (USA - CA) MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY) |
tumor infiltrating lymphocyte (TIL) |
|
- manufaturing - bioproduction
|
Technology - Services |
Production agreement |
| 2018-10-18 |
Xyphos Biosciences (USA - CA) The Parker Institute for Cancer Immunotherapy (USA - CA) |
universal CAR-T therapies based on convertibleCAR’® platform |
|
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2018-10-17 |
Recombinetics (USA - MN) Mayo Clinic (USA - MN) |
regenerative stem cell therapies |
|
research - development - R&D |
Technology - Services - Regenerative medicine |
Research agreement |
| 2018-10-16 |
Biomarin Pharmaceutical (USA - CA) Medivation (USA - CA), now Pfizer (USA - NY) |
talazoparib (BMN 673) |
metastatic breast cancer. |
product acquisition |
Cancer - Oncology |
Milestone |
| 2018-10-16 |
Ziopharm Oncology (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-10-15 |
Medivir (Sweden) |
|
|
nomination - restructuration |
Infectious diseases |
Restructuring |
| 2018-10-15 |
Sarepta Therapeutics (USA - MA) Lysogene (France) |
LYS-SAF302 |
mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
| 2018-10-10 |
Ionis Pharmaceuticals (USA - CA) Roche (Switzerland) |
IONIS-FB-LRx |
complement-mediated diseases including geographic atrophy |
development |
Ophtalmological diseases |
Development agreement |
